CTHRPHA@EC2611A

Hengrui Medicine Receives Clinical Trial Approval for Three New Drugs, Plans to Start Trials Soon

Hengrui Medicine Submits Announcement to HKEX: Plans to Repurchase 420k A-Shares for $19.82 Million

Hengrui Medicine Announces Multiple New Drug Approvals and Outstanding GLP-1 Clinical Data

Hengrui Medicine Discloses Share Repurchase Progress as of End-May 2026: Cumulative Spend Approx. 772 Million Yuan

NMPA Approves Three Innovative Drugs from Hengrui, Jinmantai, and Northland to Market

Hengrui Medicine Subsidiary Receives Approval for Clinical Trials of HRS-1635 in B-cell Malignancies

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

Hengrui Medicine and Braveheart Bio Report Positive Phase 2 Results for HRS/BHB-1893 in Treating nHCM

Hengrui Medicine Receives Approval for Two Drug Clinical Trials

Hengrui Pharmaceutical Obtains Clinical Trial Approval Notifications for Multiple New Drugs

Huaren Pharmaceutical Receives Approval for Clinical Trials of HRS-3005

Hengrui Pharmaceutical Repurchased 12,056,200 A-shares in April

Hanson Pharmaceuticals Transfers Exclusive License of Osteoarthritis Drug to Hengrui

BOC International raises Hengrui Medicine target price to 74 HKD

Citi Gives Hengrui Medicine H Shares 'Buy' Rating with Target Price

UBS Adjusts Hengrui Medicine's Profit Forecast and Maintains Buy Rating

HENGRUI PHARMA released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue HKD 9.229 B (forecast HKD 9.384 B), actual EPS HKD 0 (forecast HKD 0.3986)

HIPINE

SOFTMEDX

SYNERTONE

TAILAM TECHCON

BIOSTAR PHARM-B

WING FUNG GROUP

GLORY HEALTH

PAN ASIA DATA H

MEDINET GROUP

600276

01276

Hengrui Pharma presented over 90 oncology studies at ASCO 2026, highlighting progress across multiple tumor types. Key findings include improved pathological complete response rates in breast cancer with camrelizumab combinations, enhanced progression-free survival in colorectal and hepatocellular cancers using ADCs and immunotherapies, and breakthroughs in prostate and bladder cancer treatments. The company also showcased data for a novel antiemetic drug, underscoring its extensive pipeline of approved medicines and investigational candidates.

PR Newswire

Hengrui Pharma

HENGRUI PHARMA

Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types

01093

03692

Analysts identify Jiangsu Hengrui, CSPC, and Hansoh as top Chinese biotech firms poised to launch drugs in Europe and the US under their own brands within 10-15 years. Driven by a boom in outlicensing deals, these companies aim to compete with global giants like Pfizer. While large licensing revenues provide capital for expansion, significant investment in clinical trials and commercial infrastructure remains a barrier, favoring established players with substantial resources.

SCMP

CSPC PHARMA

HANSOH PHARMA

Pfizer

Roche

AstraZeneca

AstraZeneca PLC

ING Groep

Bristol Myers Squibb

Macquarie Group Limited

ROCHE HOLDINGS AG

Bristol-Myers Squibb Company

Which company could become the Chinese Pfizer? Here are analysts’ top picks

KLRA

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026 | KLRA Stock News

StockTitan

Kailera Therapeutics

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026 | KLRA Stock News

01919

00763

06690

00939

00100

02476

06809

02513

01888

COSCO SHIP HOLD(01919) rose 6.68%, with a trading turnover 668.9 Million HKD, and a year-to-date rose 13.4%. ZTE(00763) rose 4.51%, with a trading turnover 3.0 Billion HKD, and a year-to-date rose 9.3%. MINIMAX-W(00100) fell 16.65%, with a trading turnover 1.8 Billion HKD, and a year-to-date rose 235.2%. VGT(02476) fell 11.18%, with a trading turnover 3.2 Billion HKD, and a year-to-date rose 75.6%.

Top Gainers&Losers

COSCO SHIP HOLD

HAIER SMARTHOME

MINIMAX-W

MONTAGE TECH

KNOWLEDGE ATLAS

KB LAMINATES

Top 5 HK Stock Gainers/Losers (>100B) (6.5)

06869

00501

02269

03690

09868

02097

YOFC(06869) rose 10.65%, with a trading turnover 7.7 Billion HKD, and a year-to-date rose 398.3%. KB LAMINATES(01888) rose 9.55%, with a trading turnover 3.2 Billion HKD, and a year-to-date rose 311.3%. HENGRUI PHARMA(01276) fell 7.05%, with a trading turnover 696.8 Million HKD, and a year-to-date fell 23%. WUXI BIO(02269) fell 7%, with a trading turnover 1.5 Billion HKD, and a year-to-date rose 3.9%.

- The Hang Seng Index decreased by 1.56%, with a year-to-date change of 0%.  
- The Hang Seng Technology Index dropped by 2.74%, accumulating an 8.3% decline this year.  
- Notable movements included Longi Green Energy rising 10.65% and gaining 398.3% year-to-date, while Hengrui Medicine fell 7.05%, with a year-to-date decline of 23%.

YOFC

OMNIVISION

WUXI BIO

MEITUAN

XPENG-W

MIXUE GROUP

Top 5 HK Stock Gainers/Losers (>100B) (6.3)

516820

513060

520690

Hengrui Pharma presented over 90 oncology studies at the 2026 ASCO Annual Meeting, highlighting progress across multiple tumor types. Key findings include improved pathological complete response rates in breast cancer with camrelizumab combinations, enhanced progression-free survival in colorectal and liver cancers using ADCs and immunotherapies, and breakthroughs in prostate and bladder cancer treatments. The company also showcased data for a novel antiemetic drug, reinforcing its extensive oncology pipeline and R&D capabilities.

prnewswire

Ping An CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng Health Care ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

01:51 ETHengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types

603259

02359

G Sachs reports that China's healthcare sector has seen muted performance in 2026, with CRO/CDMO segments up 8% YTD. The broker favors visibility-led CDMO companies and selective pharmaceutical investments, focusing on upcoming clinical data. Key players include WUXI APPTEC, HENGRUI PHARMA, and INNOVENT BIO, with significant updates expected at ASCO and ADA meetings. The domestic hospital environment remains weak, prompting a preference for companies with overseas growth potential.

AASTOCKS News

WuXi AppTec

WUXI APPTEC

Goldman Sachs

INNOVENT BIO

SKB BIO

MircroPort Medbot-B

EDGE MEDICAL-B

ANGELALIGN

GS Hldg R

G Sachs: Continue to Favor Visibility-led CDMO, Closely Watch Early Signs of Market Bottoming

CTHRPHA@EC2611A(29479.HK)

Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types

Which company could become the Chinese Pfizer? Here are analysts’ top picks

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026 | KLRA Stock News

Top 5 HK Stock Gainers/Losers (>100B) (6.5)

Top 5 HK Stock Gainers/Losers (>100B) (6.3)

01:51 ETHengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types

G Sachs: Continue to Favor Visibility-led CDMO, Closely Watch Early Signs of Market Bottoming